Glucagon and regulation of glucose metabolism

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 4 47-4, 2003, Pages

  Jiang, Guoqiang ^a   Zhang, Bei B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Diabetes; Glucagon; Glucose homeostasis; Metabolism

Indexed keywords

GLUCAGON; GLUCAGON ANTIBODY; GLUCAGON DERIVATIVE; GLUCAGON RECEPTOR; GLUCAGON[1 DEHISTIDINE 6 PHENYLALANINE 9 GLUTAMIC ACID] AMIDE; GLUCAGON[1 DEHISTIDINE 9 GLUTAMIC ACID] AMIDE; GLUCAGON[1 NATRINITROPHENYLHISTIDINE 12 HOMOARGININE]; GLUCOSE; GLUCOSE 6 PHOSPHATASE; INOSITOL 1,4,5 TRISPHOSPHATE; NEUTRALIZING ANTIBODY; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PHOSPHORYLASE KINASE; SKYRIN; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DRUG TARGETING; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HORMONE ACTION; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN RELEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0037376913     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00492.2002     Document Type: Review

References (96)

1. Ahren B and Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44: 1998-2003, 2001.
2. Akatsuka A, Singh TJ, Nakabayashi H, Lin MC, and Huang KP. Glucagon-stimulated phosphorylation of rat liver glycogen synthase in isolated hepatocytes. J Biol Chem 260: 3239-3242, 1985.
3. Band G and Jones CT. Activation by glucagon of glucose 6-phosphatase activity in the liver of the foetal guinea pig. Biochem Soc Trans 8: 586-587, 1980.
4. Band GC and Jones CT. Functional activation by glucagon of glucose 6-phosphatase and gluconeogenesis in the perfused liver of the fetal guinea pig. FEBS Lett 119: 190-194, 1980.
5. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, and Rizza RA. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 97: 2351-2361, 1996.
6. Beale E, Andreone T, Koch S, Granner M, and Granner D. Insulin and glucagon regulate cytosolic phosphoenolpyruvate carboxykinase (GTP) mRNA in rat liver. Diabetes 33: 328-332, 1984.
7. Beuers U and Jungermann K. Relative contribution of glycogenolysis and gluconeogenesis to basal, glucagon- and nerve stimulation-dependent glucose output in the perfused liver from fed and fasted rats. Biochem Int 21: 405-415, 1990.
8. Birnbaumer L, Pohl SL, Rodbell M, and Sundby F. The glucagon-sensitive adenylate cyclase system in plasma membranes of rat liver. VII. Hormonal stimulation: reversibility and dependence on concentration of free hormone. J Biol Chem 247: 2038-2043, 1972.
9. Brand CL, Jorgensen PN, Knigge U, Warberg J, Svendsen I, Kristensen JS, and Holst JJ. Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol Endocrinol Metab 269: E469-E477, 1995.
10. Brand CL, Jorgensen PN, Svendsen I, and Holst JJ. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45: 1076-1083, 1996.
11. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, and Holst JJ. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37: 985-993, 1994.
12. Burcelin R, Katz EB, and Charron MJ. Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. Diabetes Metab 22: 373-396, 1996.
13. Butler PC and Rizza HA. Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose intolerant or NIDDM patients. Diabetes 40: 73-81, 1991.
14. Carstens S and Andersen I. Intranasal glucagon in the treatment of hypoglycemia. A therapeutic possibility in the future. Ugeskr Laeger 156: 4339-4342, 1994.
15. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D, de Laszlo SE, Hacker C, Hagmann WK, MacCoss M, Chicchi GG, and Vicario PP. Characterization of a novel, nonpeptidyl antagonist of the human glucagon receptor. J Biol Chem 274: 8694-8697, 1999.
16. Castano JG, Nieto A, and Feliu JE. Inactivation of phosphofructokinase by glucagon in rat hepatocytes. J Biol Chem 254: 5576-5579, 1979.
17. Chang LL, Sidler KL, Cascieri MA, de Laszlo S, Koch G, Li B, MacCoss M, Mantlo N, O'Keefe S, Pang M, Rolando A, and Hagmann WK. Substituted imidazoles as glucagon receptor antagonists. Bioorg Med Chem 11: 2549-2553, 2001.
18. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 321: 306-320, 2001.
19. Christ B, Nath A, Bastian H, and Jungermann K. Regulation of the expression of the phosphoenolpyruvate carboxykinase gene in cultured rat hepatocytes by glucagon and insulin. Eur J Biochem 178: 373-379, 1988.
20. Christophe J. Glucagon and its receptor in various tissues. Ann NY Acad Sci 805: 31-43, 1996.
21. Christophe J. Glucagon receptors: from genetic structure and expression to effector coupling and biological responses. Biochim Biophys Acta 1241: 45-57, 1995.
22. Ciudad C, Camici M, Ahmad Z, Wang Y, DePaoli-Roach AA, and Roach PJ. Control of glycogen synthase phosphorylation in isolated rat hepatocytes by epinephrine, vasopressin and glucagon. Eur J Biochem 142: 511-520, 1984.
23. Consoli A. Role of liver in pathophysiology of NIDDM. Diabetes Care 15: 430-441, 1992.
24. De Laszlo SE, Hacker C, Li B, Kim D, MacCoss M, Mantlo N, Pivnichny JV, Colwell L, Koch GE, Cascieri MA, and Hagmann WK. Potent, orally absorbed glucagon receptor antagonists. Bioorg Med Chem 9: 641-646, 1999.
25. Dharanipragada R, Trivedi D, Bannister A, Siegel M, Tourwe D, Mollova N, Schram K, and Hruby VJ. Synthetic linear and cyclic glucagon antagonists. Int J Pept Protein Res 42: 68-77, 1993.
26. Dinneen S, Alzaid A, Turk D, and Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38: 337-343, 1995.
27. Dobbins RL, Davis SN, Neal D, Caumo A, Cobelli C, and Cherrington AD. Rates of glucagon activation and deactivation of hepatic glucose production in conscious dogs. Metabolism 47: 135-142, 1998.
28. Doi Y, Iwai M, Matsuura B, and Onji M. Glucagon attenuates the action of insulin on glucose output in the liver of the Goto-Kakizaki rat perfused in situ. Pflügers Arch 442: 537-541, 2001.
29. Freychet L, Rizkalla SW, Desplanque N, Basdevant A, Zirinis P, Tchobroutsky G, and Slama G. Effect of intranasal glucagon on blood glucose levels in healthy subjects and hypoglycaemic patients with insulin-dependent diabetes. Lancet 1: 1364-1366, 1988.
30. Furuta M, Yano H, Zhou A, Rouille Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, and Steiner DF. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 94: 6646-6651, 1997.
31. Furuta M, Zhou A, Webb G, Carroll R, Ravazzola M, Orci L, and Steiner DF. Severe defect in proglucagon processing in islet A-cells of prohormone convertase2 null mice. J Biol Chem 276: 27197-27202, 2001.
32. Hansen LH, Abrahamsen N, Hager J, Jelinek L, Kindsvogel W, Froguel P, and Nishimura E. The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon. Diabetes 45: 725-730, 1996.
33. Hanson RW and Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 66: 581-611, 1997.
34. Haymond MW and Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 24: 643-645, 2001.
35. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B, and Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413: 179-183, 2001.
36. Hippen AR. Glucagon as a potential therapy for ketosis and fatty liver. Vet Clin North Am Food Anim Pract 16: 267-282, 2000.
37. Hippen AR, She P, Young JW, Beitz DC, Lindberg GL, Richardson LF, and Tucker RW. Alleviation of fatty liver in dairy cows with 14-day intravenous infusions of glucagon. J Dairy Sci 82: 1139-1152, 1999.
38. Hruby VJ. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs. Mol Cell Biochem 44: 49-64, 1982.
39. Hruby VJ, Gysin B, Trivedi D, and Johnson DG. New glucagon analogues with conformational restrictions and altered amphiphilicity: effects on binding, adenylate cyclase and glycogenolytic activities. Life Sci 52: 845-855, 1993.
40. Huang CN, Lee KC, Wu HP, Tai TY, Lin BJ, and Chuang LM. Screening for the Gly40Ser mutation in the glucagon receptor gene among patients with type 2 diabetes or essential hypertension in Taiwan. Pancreas 18: 151-155, 1999.
41. Hvidberg A, Djurup R, and Hilsted J. Glucose recovery after intranasal glucagon during hypoglycaemia in man. Eur J Clin Pharmacol 46: 15-17, 1994.
42. Ikeda T, Hoshino T, Honda M, Takeuchi T, Mokuda O, Tominaga M, and Mashiba H. Effect of glucagon on glucose output from bivascularly perfused rat liver. Exp Clin Endocrinol 94: 383-386, 1989.
43. Iynedjian PB, Auberger P, Guigoz Y, and Le Cam A. Pretranslational regulation of tyrosine aminotransferase and phosphoenolpyruvate carboxykinase (GTP) synthesis by glucagon and dexamethasone in adult rat hepatocytes. Biochem J 225: 77-84, 1985.
44. Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, Sheppard PO, and Sprecher CA. Expression cloning and signaling properties of the rat glucagon receptor. Science 259: 1614-1616, 1993.
45. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, and Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215: 1115-1116, 1982.
46. Johnson LN, Barford D, Owen DJ, Noble ME, and Garman EF. From phosphorylase to phosphorylase kinase. Adv Second Messenger Phosphoprotein Res 31: 11-28, 1997.
47. Knudsen LB, Brand CL, Sidelmann UG, Teston K, Ling A, Madsen P, and Lau J. NNN 25-2504, a potent glucagon receptor antagonist (Abstract). Diabetes 50: A309, 2001.
48. Komjati M, Bratusch-Marrain P, and Waldhausl W. Superior efficacy of pulsatile versus continuous hormone exposure on hepatic glucose production in vitro. Endocrinology 118: 312-319, 1986.
49. Krebs EG. Phosphorylation and dephosphorylation of glycogen phosphorylase: a prototype for reversible covalent enzyme modification. Curr Top Cell Regul 18: 401-419, 1981.
50. Kurland IJ and Pilkis SJ. Covalent control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: insights into auto-regulation of a bifunctional enzyme. Protein Sci 4: 1023-1037, 1995.
51. Ladouceur GH, Cook JH, Doherty EM, Schoen WR, MacDougall ML, and Livingston JN. Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists. Bioorg Med Chem 12: 461-464, 2002.
52. Larsson H and Ahren B. Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. Diabetologia 43: 194-202, 2000.
53. Larsson H and Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23: 650-657, 2000.
54. Ling A, Hong Y, Gonzalez J, Gregor V, Polinsky A, Kuki A, Shi S, Teston K, Murphy D, Porter J, Kiel D, Lakis J, Anderes K, May J, Knudsen LB, and Lau J. Identification of alkylidene hydrazides as glucagon receptor antagonists. J Med Chem 44: 3141-3149, 2001.
55. Ling A, Plewe M, Gonzalez J, Madsen P, Sams CK, Lau J, Gregor V, Murphy D, Teston K, Kuki A, Shi S, Truesdale L, Kiel D, May J, Lakis J, Anderes K, Iatsimirskaia E, Sidelmann UG, Knudsen LB, Brand CL, and Polinsky A. Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem 12: 663-666, 2002.
56. Lins PE, Wajngot A, Adamson U, Vranic M, and Efendic S. Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia. Diabetes 32: 633-636, 1983.
57. Madsen P, Brand CL, Holst JJ, and Knudsen B. Advances in non-peptide glucagon receptor antagonists. Curr Pharm Des 5: 683-691, 1999.
58. Madsen P, Knudsen LB, Wiberg FC, and Carr RD. Discovery and structure activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 41: 5150-5157, 1998.
59. Marks JS and Botelho LH. Synergistic inhibition of glucagon-induced effects on hepatic glucose metabolism in the presence of insulin and a cAMP antagonist. J Biol Chem 261: 15895-15899, 1986.
60. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, and Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39: 1381-1390, 1990.
61. Muller L, Zhu X, and Lindberg I. Mechanism of the facilitation of PC2 maturation by 7B2: involvement in proPC2 transport and activation but not folding. J Cell Biol 139: 625-638, 1997.
62. Myers SR, Diamond MP, Adkins-Marshall BA, Williams PE, Stinsen R, and Cherrington AD. Effects of small changes in glucagon on glucose production during a euglycemic, hyperinsulinemic clamp. Metabolism 40: 66-71, 1991.
63. Okar DA and Lange AJ. Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes. Biofactors 10: 1-14, 1999.
64. Opara EC, Atwater I, and Go VL. Characterization and control of pulsatile secretion of insulin and glucagon. Pancreas 3: 484-487, 1988.
65. Paolisso G, Scheen AJ, Albert A, and Lefebvre PJ. Effects of pulsatile delivery of insulin and glucagon in humans. Am J Physiol Endocrinol Metab 257: E686-E696, 1989.
66. Parker JC, Andrews KM, Allen MR, Stock JL, and McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290: 839-843, 2002.
67. Parker JC, McPherson RK, Andrews KM, Levy CB, Dubins JS, Chin JE, Perry PV, Hulin B, Perry DA, Inagaki T, Dekker KA, Tachikawa K, Sugie Y, and Treadway JL. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes 49: 2079-2086, 2000.
68. Petersen KF and Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44: 2018-2024, 2001.
69. Pilkis SJ and Claus TH. Hepatic gluconeogenesis/glycolysis: regulation and structure/function relationships of substrate cycle enzymes. Annu Rev Nutr 11: 465-515, 1991.
70. Pilkis SJ, El-Maghrabi MR, McGrane M, Pilkis J, and Claus TH. Regulation by glucagon of hepatic pyruvate kinase, 6-phosphofructo-1-kinase, and fructose-1,6-bisphosphatase. Fed Proc 41: 2623-2628, 1982.
71. Ramachandran C, Angelos KL, and Walsh DA. Hormonal regulation of the phosphorylation of glycogen synthase in perfused rat heart. Effects of insulin, catecholamines, and glucagon. J Biol Chem 258: 13377-13383, 1983.
72. Roach PJ. Control of glycogen synthase by hierarchal protein phosphorylation. FASEB J 4: 2961-2968, 1990.
73. Rouille Y, Bianchi M, Irminger J, and Halban P. Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon. FEBS Lett 413: 119-123, 1997.
74. Rouille Y, Kantengwa S, Irminger J-C, and Halban PA. Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. JBiol Chem 272: 32810-32816, 1997.
75. Rouille Y, Westermark G, Martin S, and Steiner D. Proglucagon is processed to glucagon by prohormone convertase PC2 in alphaTC1-6 cells. Proc Natl Acad Sci USA 91: 3242-3246, 1994.
76. Shah P, Basu A, Basu R, and Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol Endocrinol Metab 277: E283-E290, 1999.
77. Shah P, Vella A, Basu A, Basu R, Schwenk WF, and Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85: 4053-4059, 2000.
78. Sherwin RS, Fisher M, Hendler R, and Felig P. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl J Med 294: 455-461, 1976.
79. Shiao LL, Cascieri MA, Trumbauer M, Chen H, and Sullivan KA. Generation of mice expressing the human glucagon receptor with a direct replacement vector. Transgenic Res 8: 295-302, 1999.
80. Shiota D, Kasamatsu T, Dib SA, Chacra AR, and Moises RS. Role of the Gly40Ser mutation in the glucagon receptor gene in Brazilian patients with type 2 diabetes mellitus. Pancreas 24: 386-390, 2002.
81. Striffler JS, Garfield SA, Cardell EL, and Cardell RR. Effects of glucagon on hepatic microsomal glucose-6-phosphatase in vivo. Diabetes Metab 10: 91-97, 1984.
82. Tan K, Tsiolakis D, and Marks V. Effect of glucagon antibodies on plasma glucose, insulin and somatostatin in the fasting and fed rat. Diabetologia 28: 435-440, 1985.
83. Toft I, Gerich JE, and Jenssen T. Autoregulation of endogenous glucose production during hyperglucagonemia. Metabolism 51: 1128-1134, 2002.
84. Unger RH. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28: 574-578, 1985.
85. Unger RH. Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27: 1691-1709, 1978.
86. Unson CG, Gurzenda EM, and Merrifield RB. Biological activities of des-Hisl[Glu9]glucagon amide, a glucagon antagonist. Peptides 10: 1171-1177, 1989.
87. Van Tine BA, Azizeh BY, Trivedi D, Phelps JR, Houslay MD, Johnson DG, and Hruby VJ. Low level cyclic adenosine 3′,5′-monophosphate accumulation analysis of [des-His1, des-Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137: 3316-3322, 1996.
88. Veneziale CM, Deering NG, and Thompson HJ. Gluconeo-genesis in isolated rat hepatic parenchymal cells. IX. Differential effects of glucagon and epinephrine on phosphofructokinase and pyruvate kinase. Mayo Clin Proc 51: 624-631, 1976.
89. Vidal-Puig A and O'Rahilly S. Metabolism. Controlling the glucose factory. Nature 413: 125-126, 2001.
90. Webb GC, Akbar MS, Zhao C, Swift HH, and Steiner DF. Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 51: 398-405, 2002.
91. Weigle DS and Goodner CJ. Evidence that the physiological pulse frequency of glucagon secretion optimizes glucose production by perifused rat hepatocytes. Endocrinology 118: 1606-1613, 1986.
92. Weigle DS, Koerker DJ, and Goodner CJ. Pulsatile glucagon delivery enhances glucose production by perifused rat hepatocytes. Am J Physiol Endocrinol Metab 247: E564-E568, 1984.
93. Westphal CH, Muller L, Zhou A, Zhu X, Bonner-Weir S, Schambelan M, Steiner DF, Lindberg I, and Leder P. The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 96: 689-700, 1999.
94. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, and Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413: 131-138, 2001.
95. Young AA, Cooper GJ, Carlo P, Rink TJ, and Wang MW. Response to intravenous injections of amylin and glucagon in fasted, fed, and hypoglycemic rats. Am J Physiol Endocrinol Metab 264: E943-E950, 1993.
96. Zhang BB and Moller DE. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 4: 461-467, 2000.